Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbrella Trial of Novel Agents in Relapsed Ovarian Cancer
NCT03267589Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology Clinical Trial Unit
- Start
- May 2018
- Primary completion
- Oct 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of oleclumab, ivuxolimab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Nordic Society of Gynaecological Oncology Clinical Trial Unit. Started May 2018; status: completed.
02
Drugs
oleclumabivuxolimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03267589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03267589.